[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zymeworks BC Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100605576",false,"NCT07164313","A Study of ZW251 in Participants With Advanced Solid Tumors","A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and\u002For metastatic disease. Noninvasive methods may be used to confirm diagnosis\n* Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and\u002For metastatic disease\n* Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and\u002For choriocarcinoma predominant component and locally advanced (unresectable) and\u002For metastatic disease\n* Measurable disease per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Liver function status of Child-Pugh Class A (for HCC only)\n* Adequate organ function\n\nExclusion Criteria:\n\n* Known additional malignancy that is progressing or that has required active treatment within the last year\n* History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy\n* Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment\n* Known gastrointestinal bleeding within 3 months\n* Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).",[25,26,27],"Hepatocellular Carcinoma","Squamous Cell Non-Small Cell Lung Cancer","Germ Cell Tumor",[29,30,31,32,33,34,35,27],"GPC3-expressing cancer","hepatocellular carcinoma","antibody drug conjugate","ADC","Lung Cancer","Non-Small Cell Lung Cancer","Squamous Cell Cancer","RECRUITING","2026-05-05",{"date":39,"type":40},"2026-05-07","ACTUAL",{"date":42,"type":40},"2025-10-21",{"date":44,"type":19},"2028-05",{"name":46,"class":47},"Zymeworks BC Inc.","INDUSTRY",25,""]